Category Archives: Investment

Week’s opening stock salvo: Cellect, Impax, Cancer Genetics celebrate; Foamix, not so much

After the resounding thud heard round-the-world Friday upon the failure of Trumpcare, healthcare stocks were back in vogue with investors Monday (March 27, 2017). Here are the top stars and… Read more »

Stock markets closed Friday prior to collapse of Trumpcare; health sector’s biggest winners & losers as of March 24, 2017

Republican bickering has led to the biggest rout yet for President Trump’s early administration. As I expected, the GOP plan to gut the Affordable Care Act collapsed Friday (March 24,… Read more »

PTC Therapeutics catches falling knife with Emflaza buy; or did it?

Every now and again I’ll read about what seems on its face a boneheaded business deal between two Pharma companies and try to blow the lid off some super-stealthy, strategic,… Read more »

Week’s opening stock salvo: Esperion, Nektar, CytomX soar; Aevi Genomic thrashed

Esperion Therapeutics Inc. (Nasdaq: ESPR) stock recently recovered big time from last Amgen-induced beat down to touch an 18-month high after the company outlined its path to FDA approval for its… Read more »

After 15 years, unheralded French biotech eyeing big payday on cancer breakthrough; “buy” signal–solid

Hidden from view just across the French border from Geneva is a little-known (at least here in the US) biotech eyeing long-awaited FDA approval for a nuclear medicine targeting the… Read more »

Health sector’s biggest winners & losers as of March 17, 2017

Seres Therapeutics Inc. (Nasdaq: MCRB) led advancing issues, soaring $2.71, or 29% for the week, to $12.04. The small microbiome-therapeutics platform company released its fourth-quarter results earlier Thursday (March 16,… Read more »